BioInvent: Funding, Investors & Team (Oct 2026)
BioInvent is an innovative pharmaceutical company that focuses on developing antibody drugs to target high need cancers through research. The company's drug development programs utilize a human antibody development platform that comprises a patented antibody library, n-CoDeR:registered:, and in-house technology that enables swift selection, screening, and identification of antibodies that exhibit excellent affinity and selectivity for targets. BioInvent has substantial expertise in preclinical and clinical development, antibody drug discovery, as well as experience in process development and manufacturing, which they do in their own facilities. Customers can avail of antibody discovery and development services alongside BioInvent's own and collaborative drug-development programs. The company has an outstanding track record validated by numerous partnerships with Bayer, Daiichi Sankyo, Mitsubishi Tanabe, Servier, and others. BioInvent employs approximately 50 people and is headquartered in Lund, Sweden, with a listing on NASDAQ OMX Stockholm since 2001.
BioInvent has raised $3.0M across 1 funding round on record, the most recent an undisclosed round of $3.0M announced in Apr 2023.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioInvent Company Profile and Key Stats
Latest funding round on record: Apr 2023.
BioInvent Funding Rounds
BioInvent Founders and Leadership Team
Contact details for the BioInvent team: 1 of 1 has an email address on file.
Start 14-day free trial →BioInvent Funding Compared to Other Biotechnology Startups
BioInvent's latest round of $3.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioInvent in Biotechnology and Lund
Companies Similar to BioInvent
Our ambition is to play a key role in tackling climate change, by enabling green chemistry for every…
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic…
Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally.
Our vision is to develop and bring to the market safe and effective treatments for women specific diseases…
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer…
Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for…
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for…
Moleculent is dedicated to creating tech-based products that utilize fresh knowledge about the molecular…
Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge…
Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in…
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic…
BioInvent Funding FAQs
What does BioInvent do?
BioInvent is an innovative pharmaceutical company that focuses on developing antibody drugs to target high need cancers through research. The company's drug development programs utilize a human antibody development platform that comprises a patented antibody library, n-CoDeR:registered:, and in-house technology that enables swift selection, screening, and identification of antibodies that exhibit excellent affinity and selectivity for targets. BioInvent has substantial expertise in preclinical and clinical development, antibody drug discovery, as well as experience in process development and manufacturing, which they do in their own facilities. Customers can avail of antibody discovery and development services alongside BioInvent's own and collaborative drug-development programs. The company has an outstanding track record validated by numerous partnerships with Bayer, Daiichi Sankyo, Mitsubishi Tanabe, Servier, and others. BioInvent employs approximately 50 people and is headquartered in Lund, Sweden, with a listing on NASDAQ OMX Stockholm since 2001.
How much funding has BioInvent raised?
BioInvent has raised $3.0M across 1 round on record. The most recent is an undisclosed round of $3.0M announced in Apr 2023.
When did BioInvent last raise funding?
BioInvent's most recent funding round on record is an undisclosed round of $3.0M, announced in Apr 2023.
Who founded BioInvent?
FundedIQ lists Bjorn Frendeus (Founder) at BioInvent.
Where is BioInvent headquartered?
BioInvent is based in Lund, Skane Lan, Sweden.
How many employees does BioInvent have?
BioInvent is in the 101-250 employee band.
How does BioInvent's funding compare to other Biotechnology startups?
BioInvent's latest round of $3.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's BioInvent Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioInvent is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.